Jubliant Life Sciences in Non-Exclusive Agreement for Gilead Covid-19 Drug --Reuters
May 12 2020 - 3:12PM
Dow Jones News
--India-based Jubilant Life Sciences Ltd. has reached a
non-exclusive licensing agreement to sell Gilead Sciences Inc.'s
Covid-19 treatment remdesivir in 127 countries, Reuters reported
Tuesday.
--Jubliant will also have manufacturing rights in many
countries, the report said.
--Last week, Gilead said it would work with other companies to
manufacture and sell remdesivir outside of the U.S. and was
negotiating with drugmakers in India and Pakistan to grant
long-term licenses to sell generic versions.
Full story:
https://www.reuters.com/article/us-health-coronavirus-gilead-sciences/indias-jubilant-signs-licensing-deal-for-gileads-potential-covid-19-drug-idUSKBN22O2HJ
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 12, 2020 14:57 ET (18:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024